For example, combining chloroquine with RT and ICIs could enhance the effectiveness of immune-RT, while adding RT, chloroquine, and/or IFNα to standard ICI therapy at relapse may restore the immune recognition of cancer cells and extend the disease remission already achieved by ICIs. Here, IFNA1 is linked to cancer.